These results demonstrate that the orthoquinone moiety is a key pharmacophore for IDO1 and HDAC1 inhibition, providing a potential strategy for cancer treatment by exploiting both immunotherapeutic and epigenetic drugs [33]. The gene discussed is IDO1; the disease is cancer.